Guska, one of the startups in the LAB+ portfolio, has announced the addition of Antonio Bordería as Senior Business Advisor. Bordería is a former researcher at the Institut Pasteur in Paris, holds a PhD in molecular biology, and currently serves as Vice President at a tech company focused on artificial intelligence and data. “I’m excited to be part of the startup because I believe we can make a real impact on cancer patients,” he said.
In 2010, Bordería joined the Institut Pasteur in Paris as a postdoctoral researcher, later becoming a scientific project manager in the Department of Computational Biology. Over time, he took on the role of Director of Business Development, focusing on the commercialization of software, AI models, and data generated within the institute.
Since 2022, he has been serving as VP of Business Development and Strategic Partnerships at ADLIN Science, a tech company dedicated to enabling responsible access and use of biomedical data. In this role, he leads efforts to accelerate drug discovery by improving access to high-quality data, developing AI models, and fostering industry collaborations. This expertise positions him to support Guska both in licensing and contracts, as well as in its strategic development.
“My main role at Guska is to help build out its strategic and commercial side. We’re thinking about how to generate interest from pharmaceutical companies—many of which are working on new approaches to fight cancer,” he said.
“My job is also about bringing new perspectives on where the most promising business opportunities lie and how we can reposition ourselves. Right now, Guska is very biotech-focused in the traditional sense: developing molecules and licensing them to pharma companies. I want to bring in a slightly different approach—more and more, we’re seeing how AI systems are transforming therapeutic development. Here in France, where I’m based, I see many startups where biology is still key, but they lean more toward a tech-driven model. They use massive, multimodal data (from different sources) to build models that help us better understand biological complexity. AI models are well-suited to uncover biological patterns that can speed up drug development,” he explained.
In that regard, he noted, “Guska’s model fits well within the biotech vision, but also aligns with the techbio approach. Just imagine if we could consolidate data generated in Guska’s lab and build biological models to validate our future predictions. That could lead to new molecules or drug candidates—and scale the company in a very exciting way.”
“I want to bring that broader, global vision—something we’re seeing a lot in Europe—and I believe Guska has the potential to reach that level,” he said.
He also said that he joined Guska “because of the team”. He met one of the founders, Gonzalo Moratorio, when they were both doing their postdocs at the Institut Pasteur in Paris, and witnessed “part of Guska’s origin story.” “I’m really excited to work with him and with Pilar (Moreno, co-founder) because I know they share the same vision of making an impact on patients. I believe Guska has a bright future, and I’ll do everything I can to help make that happen,” he said.
“I’ll be right there, on the front lines. As I always tell Gonzalo and Pilar: we’re all in this together, and we’re pushing forward as one team,” he concluded.
